Derma Sciences Inc. (NASDAQ:DSCI) shares traded up 6.2% during mid-day trading on Wednesday . The company traded as high as $4.48 and last traded at $4.31, with a volume of 170,911 shares trading hands. The stock had previously closed at $4.06.

Separately, Zacks Investment Research lowered Derma Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Derma Sciences currently has an average rating of “Hold” and a consensus target price of $7.45.

The firm’s market cap is $124.26 million. The firm has a 50-day moving average price of $4.07 and a 200 day moving average price of $3.61.

Derma Sciences (NASDAQ:DSCI) last released its earnings results on Wednesday, May 11th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $20.20 million for the quarter, compared to the consensus estimate of $20.60 million. On average, equities research analysts expect that Derma Sciences Inc. will post ($0.20) EPS for the current fiscal year.

An institutional investor recently raised its position in Derma Sciences stock. Royce & Associates LLC boosted its position in Derma Sciences Inc. (NASDAQ:DSCI) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 237,507 shares of the company’s stock after buying an additional 16,000 shares during the period. Royce & Associates LLC owned 0.92% of Derma Sciences worth $1,085,000 as of its most recent filing with the SEC.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.